Venue Analysis Following 1st Chinese Patent Office Rulings

Venue Analysis Following 1st Chinese Patent Office Rulings

October 21, 2022, Law360

The China National Intellectual Property Administration recently made two benchmark administrative rulings in a major patent infringement dispute. The case was brought by international innovator drug company Boehringer Ingelheim Pharma GmbH & Co. KG against two Chinese generic drug makers Guangdong HEC Pharmaceutical Co. Ltd. and Yichang HEC Changjiang Pharmaceutical Co. Ltd., and a series of injunctions were granted against the two generic drug makers.